KILR® U2OS PD-L1 Cell Line

The KILR® U2OS PD-L1 Cell Line allows for assay of effector-induced cell death by a variety of immune mechanisms. This cell line ships as two vials of cryopreserved cells.

Catalog #: 97-1029C003 Size: 2 vials

Inquire

Biological Information
Background Information:	The KILR® U2OS PD-L1 cell line is a stable, engineered target cell line to measure direct cell death mediated by immunooncology treatments (e.g. checkpoint inhibitors, checkpoint agonists, bispecifics, CAR-T, and more) via Antibody Dependent Cell-mediated Cytotoxicity (ADCC), Complement Dependent Cytotoxicity (CDC), and Antibody Dependent Cell Phagocytosis (ADCP). This product uses EFC technology. The cell line overexpresses a PL- tagged housekeeping gene. Once the cells have been lysed by effector cells, PL is released to the media, where EA contained in the detection kit produces an EFC signal proportional to the level of PL released. This allows for calculation of percent lysis of the KILR® cell line. This stable modified cell line is provided as two vials of cryopreserved cells.
Target Class:	Checkpoint Receptor
Family:	IgSF (immune inhibitory Receptor ligand)
Accession Number:	NM_014143.3
Target Name:	PD-L1
Target Aliases:	Programmed cell death 1 ligand 1, B7-H, B7H1, PDL1, PD-L1, hPD-L1, PDCD1L1, PDCD1LG1, CD274
Target Species:	Human
Cell Background:	U2OS

Usage
Product Type:	Stable Cell Lines
Application:	Drug Discovery & Development
Storage Conditions:	Store in vapor phase of liquid nitrogen.
Usage Disclaimer:	These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Assay Information
Assay Type:	Functional
Assay Measures:	Cytotoxicity
Detection Method:	Chemiluminescence

Clinical Relevance
Therapeutic Area:	Oncology/Immuno-Oncology

Additional Information
Brand:	KILR®